This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Safety & Activity of First-in-Class Dual AR Degrader & Antagonist BMS-986365 in Heavily Pretreated mCRPC Patients

24 views
October 16, 2024
Comments 0
Login to view comments. Click here to Login